

25 August 2016

## CHRIS GALLAHER ELECTED AS NEW CHAIRMAN FOR PACIFIC EDGE BOARD

The Board of cancer diagnostics company, Pacific Edge Limited (NZX: PEB) has announced the election of Mr Chris Gallaher as Chairman, replacing Mr Chris Swann who, as previously advised, is stepping down from the Board at today's Annual Shareholders' Meeting.

Chris Gallaher was appointed to the Pacific Edge Board in July 2016. He is an internationally experienced senior executive, with significant financial and risk management expertise. He has held a number of senior roles, including CEO of Village Roadshow and most recently as Group Chief Financial Officer of Fulton Hogan.

Mr Gallaher said he was looking forward to stepping into the role. "Pacific Edge is an exciting company with world leading products. It has positioned itself well to win in the world's largest healthcare market, the USA, and is gaining good traction in other markets. The company has enormous potential and is creating significant value, both for society through better health outcomes, and for our shareholders. The task for the company is to continue its growth and its delivery of that potential."

Pacific Edge would like to acknowledge the contribution made by Chris Swann during his 11 years on the Board. During his tenure, Pacific Edge has evolved from a research organisation to a commercial entity, with a well-developed commercial strategy, market operations in New Zealand, Australia and the USA and a 'one stop shop' of bladder cancer diagnostic products.

Mr Swann said: "I have been privileged to be part of Pacific Edge's journey as we have grown and built our international business. Pacific Edge is leading the way in molecular diagnostics for bladder cancer patients, and we are now seeing growing acceptance and demand for our easy to use, accurate and cost effective Cxbladder tests. I leave Pacific Edge knowing that it is in good hands, with a strong Board and an experienced and highly capable executive team."

**ENDS**

### **For more information contact:**

David Darling  
Chief Executive Officer  
Pacific Edge Ltd  
P: +64 (3) 479 5800

### **OVERVIEW** [www.pacificedge.co.nz](http://www.pacificedge.co.nz) [www.pacificedgedx.com](http://www.pacificedgedx.com)

Pacific Edge Limited (NZX: PEB) is a New Zealand publicly listed, cancer diagnostic company specialising in the discovery and commercialisation of diagnostic and prognostic tests for better detection and management of cancer. The company is developing and commercialising its range of Cxbladder bladder cancer tests globally through its wholly owned central laboratories in New Zealand and the USA. The company's products have been tested and validated in international multi-centre clinical studies.

Pacific Edge has three proprietary, novel, accurate, molecular diagnostic products in-market providing actionable results, and better detection and management of urothelial cancer. Cxbladder Detect is available through the company's dedicated CLIA certified laboratories for customers in New Zealand, Australia and the USA. Cxbladder Triage is available in New Zealand and Australia. Cxbladder Monitor launched in New Zealand in December 2015 and is anticipated being available in the US in 2016.

**ABOUT Cxbladder Triage** [www.cxbladder.com](http://www.cxbladder.com)

Cxbladder Triage combines the power of the genomic biomarkers with additional phenotypic and clinical risk factors to accurately identify patients with haematuria who have a low probability of bladder cancer and may not require a more extensive urological evaluation. Cxbladder Triage is a tool for use by clinicians and physicians in primary evaluation of patients with hematuria and is intended to reduce the need for an expensive and invasive work-up in patients who have a low probability of having urothelial carcinoma.

**ABOUT Cxbladder Detect** [www.cxbladder.com](http://www.cxbladder.com)

Cxbladder Detect enables the non-invasive detection of bladder and other urinary tract cancers from a small volume of a patients' urine. Cxbladder Detect was launched in 2013 in the USA and is commercially available in New Zealand, Australia and the USA as a Laboratory Developed Test (LDT) from the company's CLIA certified laboratories. Cxbladder Detect provides physicians and clinicians with a quick, cost effective and accurate measure of the presence of the cancer as an effective adjunct to cystoscopy.

**ABOUT Cxbladder Monitor** [www.cxbladder.com](http://www.cxbladder.com)

Cxbladder Monitor, the third test in the Cxbladder portfolio for urologists, is a proprietary, non-invasive, molecular diagnostic test that combines genomic biomarkers measured from a small quantity of a patient's urine, with patient specific clinical factors to better monitor bladder cancer patients for recurrence. Bladder cancer has a recurrence rate of 50-80% and requires life-long surveillance. Cxbladder Monitor accurately identifies patients with a prior history of urothelial cancer (UC) whose Cxbladder Monitor score shows that they have a low probability of recurrent urothelial carcinoma. Cxbladder Monitor is designed to be used as the preferred adjunct test to cystoscopy in the management of patients for ongoing evaluation of recurrent bladder cancer.

Refer to [www.cxbladder.com](http://www.cxbladder.com) for more information.